Oral fluoroquinolones and risk of aortic dissection and aortic aneurysm: a nationwide nested case-control study

26 August 2022 (08:00 - 19:30)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Jarl Emanuel Strange

Herlev and Gentofte Hospital, Copenhagen (Denmark)

6 More presentations in this session

Presentation thumbnail

Berberine associated to SGLT2i Dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to Trastuzumab through reduction of AGEs and IL-6 and induction of pAMPK

Doctor N. Maurea (Naples, IT)

Abstract Slides

Presentation thumbnail

Dose-dependency of diclofenac's cardiovascular risks: a series of nationwide emulated trials

Associate Professor M. Schmidt (Aarhus, DK)

Abstract Slides

Presentation thumbnail

Cardiovascular risk following cannabinoid treatment for patients with chronic pain

Mrs N. Nouhravesh (Durham, US)

Abstract Slides

Presentation thumbnail

Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissue

Doctor N. Maurea (Naples, IT)

Abstract Slides

Presentation thumbnail

Incidence of drug-drug interactions of QT-prolonging drugs in an onco-hematological outpatient

Mr E. Fort (Barcelona, ES)

Abstract Slides

Access the full session

Session thumbnail

Drug cardiotoxicity: what do we need to know?

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

You may be interested in

Congress Presentation

Can we accurately predict cardiovascular complications in targeted cancer therapies?

Webinar

Multidisciplinary strategies for monitoring and managing cardiovascular toxicity in patients with cancer

Congress Presentation

Treatment options for cancer therapy-related cardiac dysfunction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources